FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078705274> ?p ?o ?g. }

• W2078705274 endingPage "279" @default.
• W2078705274 startingPage "273" @default.
• W2078705274 abstract "International Journal of DermatologyVolume 25, Issue 5 p. 273-279 Interferons in the Treatment of Skin Disease Q. Scott Ringenberg M.D., Q. Scott Ringenberg M.D. From the Divisions of Hematology and Dermatology, University of Missouri-Columbia, Columbia, MissouriSearch for more papers by this authorPhilip C. Anderson M.D., Corresponding Author Philip C. Anderson M.D. From the Divisions of Hematology and Dermatology, University of Missouri-Columbia, Columbia, MissouriAddress for correspondence: Philip C. Anderson, M.D., Division of Dermatology, Department of Medicine, University of Missouri-Columbia, Columbia, MO 65212, See also page 294.Search for more papers by this author Q. Scott Ringenberg M.D., Q. Scott Ringenberg M.D. From the Divisions of Hematology and Dermatology, University of Missouri-Columbia, Columbia, MissouriSearch for more papers by this authorPhilip C. Anderson M.D., Corresponding Author Philip C. Anderson M.D. From the Divisions of Hematology and Dermatology, University of Missouri-Columbia, Columbia, MissouriAddress for correspondence: Philip C. Anderson, M.D., Division of Dermatology, Department of Medicine, University of Missouri-Columbia, Columbia, MO 65212, See also page 294.Search for more papers by this author First published: June 1986 https://doi.org/10.1111/j.1365-4362.1986.tb02242.xCitations: 15AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Yancey KB, SmJih JG. Interferon: status in treatment of skin disease. I Am Atad Dermatol. 1980; 3: 585–595. 2 Hawkins MJ, Drown SE, Borden EC, et al. American Cancer Society phase I trial of naturally produced bera-interferon. Cancer Res. 1984; 44: 5934–5938. 3 Yarbov A. Interferon; anticancer agent having multifarious activity. Prog Clin Cancer. 1982: 9: 99–145. 4 Ho, M. Recent advances in the study of interferon. Pharmacol Rev. 1982; 34: 119–129. 5 Creasey AA, Merigan TC. Advances in Interferon research. West J Med. 1982; 136: 227–235. 6 StJehm ER, Kronenberg LH, Rosenblatt HM, et al. Interferon: immunobiology and clinical significance. Ann Intern Med. 1982; 96: 80–93. 7 Sikoros K. Interferon and cancer. New York : Plenum Press. 1983. 8 Gutterman JM, Eine S, Quesada J, et al. Recombinant leukocyte A interferon: pharniacokinetics, single-dose tolerance and biological effects in cancer patients. Ann Intern Med. 1982; 96: 549–556. 9 Rohatiner AZS, Prior PF, Burton AC, et al. Central nervous system toxicity of interferon. Br J Cancer. 1983; 47: 419–422. 10 Gutterman JU, Blumenschein R, Alexanian R, et al. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med. 1980; 93: 399–406. 11 Krown SE, Burk MW, Kirkwood JM, et al. Hum a n leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial. Cancer Treat Rep. 1984; 68: 723–726. 12 Ernstoff MS, Reiss M, Davis CA, et al. Intravenous (IV) recombinant alpha 2 interferon (IFN–alpha2) in metastatic melanoma. Proc Am Soc Clin Oncol. 1983; 2: 57. 13 Creagan ET, Ahmann DL, Green SJ, et al. Phase II study of recombinant leukocyte A interferon (rIEN–alpha A) in disseminated malignant melanoma. Cancer. 1984, 54: 2844–2849. 14 Robinson WA, Kirkwood J, Harvey H, et al. Effective use of recombinant human alpha-2 interferon in metastatic malignant melanoma. Proc Am Soc Clin Oncol. 1984; 3: 60. 15 Abrarm PC, Sherwin SA, Ward J, et al. A phase I trial of recombinant leukocyte A interferon administered by intralesional injection. Proc ASCO. 1983; 2: 48. 16 Krown SE, Real RX, Cunningham Rundles S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med, 1933; 308: 1071–1076. 17 Groopman JE, Gottlieb MS, Goodman J, et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med. 1984; 100: 671–676. 18 Bunn PA, Eoon K, Ihde DC, et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med. 1984; 101: 484–487. 19 Pazin GJ, Armstrong JA, Lam MT, et al. Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. N Engl J Med. 1979; 301: 225–230. 20 Ho M, Pazin GJ, Armstrong JA, et al. Paradoxical effects of interferon on reactivation of oral infection with herpes simplex virus after microvascular dec ompression for trigeminal neuralgia. J Infect Dis. 1984: 150: 867–872. 21 Ostler JB, Okumoto M. Corneal intections. In: PD Hoeprich, ed. Infectious diseases. Philadelphia : Harper and Row, 1983; 1371–1376. 22 Jones BR, Coster DJ, Ealcon MG. Topical therapy of ulcerative herpes keratitis with human interferon. Lancet. 1976; 2: 128. 23 Jones BR, Coster DJ. Falcon MG, et al. Clinical trial of topical interferon therapy of ulcerative viral keratitis. J Infect Dis. 1976; 133 (suppl A): A169–A172. 24 Kaufman HE, Meyer RF, Laibson PR, et al. Human leukocyte interferon for the prevention of recurrences of herpes keratitis. J Infect Dis. 1976; 133 (suppl A): A165–A168. 25 Marcy SM, Kibrich S. Varicella and herpes zoster. In: PD. Hoeprich ed. Infectious diseases, Philadelphia : Harper and Row, 1983: 876–892. 26 Arvin AM. Kushner JH, Feldman S. et al. Human leukocyte interferon for the treatment of varicella in children with cancer. N Engl J MedM, 1982; 306: 761–765. 27 Weller TH. Varicella and herpes zoster. N Engl J Med. 1983; 309: 1434–1440. 28 Emodi G, Rufli T, Just M, et al. Human interferon therapy for herpes zoster in adults. Scand I Infect Dis. 1975; 7: 1–5. 29 Merigan TC, Gallagher JG, Pollard RB, et al. Short course human leukocyte interferon in treatment of herpes zoster in patients with cancer. Antimicrob Agenis Chemother. 1981; 19: 193–195. 30 Goepfert H, Sessions RB, Gutterman JU, et al. Leukocyte interferon in patients with juvenile laryngeal papillomatosis. Ann Otol Rhinol Laryngol. 1982; 91: 431–436. 31 Schonfeld A, Nitke S. Schattner A. et al. Intramuscular human interferon-beta injections in treatment of condyulomata acuminata. Lancet. 1984; 1 (8385): 1038–1042. 32 Lundquist PG, Haglund S, Carlsoo B, et al. Interferon therapy in juvenile laryngeal papillomatosis. Otolaryngol Head Neck Surg. 1984; 92: 386–391. 33 Haglund S, Lundquist P, Cantell K, et al. Interferon therapy in juvenile laryngeal papillomatosis. Arth Otolaryngol. 1981: 107: 327–332. 34 McCabe BF, Clark KF. Interferon and laryngeal papillomatosis. Ann Otol Rhinol Laryngol. 1983; 92: 2–7. 35 Bombolt A. Interferon therapy for laryngeal papillomatosis in adults. Arch Otolaryngol. 1983; 109: 550–552. 36 Vesterinen E, Meyer B, Purola E, et al. Treatment of vaginal flat condyloma with interferon cream (letter). Lancet. 1984: 1(8369): 157. 37 Scott GM, Csonka GW. Effect of injections of small doses of human fibroblast interferon into genital warts: a pilot study. Br J Vener Dis. 1979; 55: 442–445. 38 Geffen JR, Klein RJ, Friedman-Kien AE. Intralesional administration of large doses of human leukocyte interferon for the treatment of condylomata acuminata. J Infect Dis. 1984; 150: 612–615. 39 Bjerke JR, Degre M, Haukenes G, et al. T cells, interferons and retrovirus-like particles in psoriatic lesions. Acta Derm Venereol (Stockh). 1984; 113 (suppl): 29–33. 40 Nickoloff BJ. Eymphocyte-keratinocyte interactions mediated through interferon. New observations relevant to psoriasis. Cutis. 1984; 34: 445–446. 41 Diezel W, Waschke SE, Sonnichsen N. Detection of interferon in the sera of patients with psoriasis, its enhancement by PUVA treatment. Br J Dermatol. 1983; 109: 549–552. 42 Kariniemi A-L. Effect of human leukocyte interferon and DNA synthesis in human psoriatic skin cultured in diffusion chambers. Acta Pathol Microbiol Immunol Scand [A]. 1977; 85: 270–272. Citing Literature Volume25, Issue5June 1986Pages 273-279 ReferencesRelatedInformation" @default.
• W2078705274 created "2016-06-24" @default.
• W2078705274 creator A5030490440 @default.
• W2078705274 creator A5044221037 @default.
• W2078705274 date "1986-06-01" @default.
• W2078705274 modified "2023-09-28" @default.
• W2078705274 title "Interferons in the Treatment of Skin Disease" @default.
• W2078705274 cites W1963897060 @default.
• W2078705274 cites W1974891829 @default.
• W2078705274 cites W2015624972 @default.
• W2078705274 cites W2018690866 @default.
• W2078705274 cites W2018875583 @default.
• W2078705274 cites W2020336513 @default.
• W2078705274 cites W2040423395 @default.
• W2078705274 cites W2044911584 @default.
• W2078705274 cites W2052677652 @default.
• W2078705274 cites W2056030233 @default.
• W2078705274 cites W2066957976 @default.
• W2078705274 cites W2068507230 @default.
• W2078705274 cites W2089433411 @default.
• W2078705274 cites W2108519688 @default.
• W2078705274 cites W2110151585 @default.
• W2078705274 cites W2115660119 @default.
• W2078705274 cites W2120600949 @default.
• W2078705274 cites W2125563766 @default.
• W2078705274 cites W2128394628 @default.
• W2078705274 cites W2131273552 @default.
• W2078705274 cites W2131788586 @default.
• W2078705274 cites W2137152057 @default.
• W2078705274 cites W2144360148 @default.
• W2078705274 cites W2290123971 @default.
• W2078705274 cites W2326242884 @default.
• W2078705274 cites W2338176289 @default.
• W2078705274 cites W4242733658 @default.
• W2078705274 cites W4248015275 @default.
• W2078705274 doi "https://doi.org/10.1111/j.1365-4362.1986.tb02242.x" @default.
• W2078705274 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2424849" @default.
• W2078705274 hasPublicationYear "1986" @default.
• W2078705274 type Work @default.
• W2078705274 sameAs 2078705274 @default.
• W2078705274 citedByCount "15" @default.
• W2078705274 crossrefType "journal-article" @default.
• W2078705274 hasAuthorship W2078705274A5030490440 @default.
• W2078705274 hasAuthorship W2078705274A5044221037 @default.
• W2078705274 hasConcept C142724271 @default.
• W2078705274 hasConcept C16005928 @default.
• W2078705274 hasConcept C2779134260 @default.
• W2078705274 hasConcept C71924100 @default.
• W2078705274 hasConceptScore W2078705274C142724271 @default.
• W2078705274 hasConceptScore W2078705274C16005928 @default.
• W2078705274 hasConceptScore W2078705274C2779134260 @default.
• W2078705274 hasConceptScore W2078705274C71924100 @default.
• W2078705274 hasIssue "5" @default.
• W2078705274 hasLocation W20787052741 @default.
• W2078705274 hasLocation W20787052742 @default.
• W2078705274 hasOpenAccess W2078705274 @default.
• W2078705274 hasPrimaryLocation W20787052741 @default.
• W2078705274 hasRelatedWork W1506200166 @default.
• W2078705274 hasRelatedWork W1995515455 @default.
• W2078705274 hasRelatedWork W2048182022 @default.
• W2078705274 hasRelatedWork W2080531066 @default.
• W2078705274 hasRelatedWork W2748952813 @default.
• W2078705274 hasRelatedWork W2899084033 @default.
• W2078705274 hasRelatedWork W3031052312 @default.
• W2078705274 hasRelatedWork W3032375762 @default.
• W2078705274 hasRelatedWork W3108674512 @default.
• W2078705274 hasRelatedWork W4297184974 @default.
• W2078705274 hasVolume "25" @default.
• W2078705274 isParatext "false" @default.
• W2078705274 isRetracted "false" @default.
• W2078705274 magId "2078705274" @default.
• W2078705274 workType "article" @default.